{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:45:57Z","timestamp":1782715557985,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Renal cell carcinoma (RCC) is increasingly managed with a broad range of systemic and local therapies, creating new challenges for imaging-based response assessment in metastatic disease. While conventional size-based criteria such as RECIST v1.1 remain widely used, they incompletely capture the diverse morphologic and functional changes induced by modern treatment. Targeted therapies, including vascular endothelial growth factor receptor tyrosine kinase inhibitors and other pathway-directed agents, may produce necrosis, devascularisation, and prolonged disease stability without substantial tumour shrinkage. Immune checkpoint inhibitors introduce additional atypical response patterns, including pseudoprogression, mixed response, and rarely hyperprogression, which can complicate early interpretation of surveillance imaging. Combination regimens may demonstrate features of both targeted and immune-mediated response. In parallel, stereotactic body radiotherapy has emerged as an important treatment for oligometastatic and oligoprogressive RCC, with imaging appearances that may include lesion shrinkage, stability, or transient enlargement following treatment. This review summarises the current treatment landscape for metastatic RCC and the imaging manifestations of response across chemotherapy, targeted therapy, immunotherapy, combination systemic therapy, and stereotactic radiotherapy. It discusses the strengths and limitations of conventional and modified response criteria, including RECIST v1.1, iRECIST, attenuation-based CT criteria, and morphology-based approaches. The review also highlights the evolving role of functional and novel imaging techniques, including diffusion-weighted whole-body MRI, dual-energy and spectral CT, and PET\/CT, as potential tools for improving response assessment beyond size alone. In addition, key imaging features of treatment-related toxicity are reviewed. Familiarity with these response patterns and complications is essential for radiologists involved in the care of patients with metastatic RCC, particularly as treatment strategies become increasingly multimodal and biologically complex.<\/jats:p>","DOI":"10.1007\/s00261-026-05604-z","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:05:21Z","timestamp":1782709521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imaging response assessment in metastatic renal cell carcinoma: a radiologist\u2019s guide to contemporary therapeutic strategies"],"prefix":"10.1007","author":[{"given":"Samuel J.","family":"Withey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iztok","family":"Caglic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derfel","family":"ap Dafydd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kelly-Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam","family":"Sohaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherry","family":"Sit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick M.","family":"Remer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maka","family":"Kekelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"5604_CR1","unstructured":"National Cancer Institute. Cancer Stat Facts: Kidney and Renal Pelvis Cancer [Internet]. Bethesda (MD): National Cancer Institute; [cited 2026 March 17]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html"},{"issue":"45","key":"5604_CR2","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.3346\/jkms.2024.39.e293","volume":"39","author":"CH Lee","year":"2024","unstructured":"Lee CH, Kang M, Kwak C, Ko YH, Kim JK, Park JY, et al. Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database. J Korean Med Sci. 2024;39(45):e293.","journal-title":"J Korean Med Sci"},{"issue":"12","key":"5604_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","volume":"24","author":"YW Chen","year":"2023","unstructured":"Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, et al. Treatment Landscape of Renal Cell Carcinoma. Curr Treat Options Oncol. 2023;24(12):1889\u2013916.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"5604_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Gr\u00fcnwald V, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2024;35(8):692\u2013706.","journal-title":"Annals of Oncology"},{"key":"5604_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Kidney Cancer. Version 2.2026: National Comprehensive Cancer Network; 2026 [Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1440."},{"issue":"8","key":"5604_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573\u201384.","journal-title":"Nat Rev Cancer"},{"key":"5604_CR7","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 1990). 2009;45(2):228\u2009\u2013\u200947.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"21","key":"5604_CR8","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2011.36.4752","volume":"30","author":"RK Jain","year":"2012","unstructured":"Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30(21):2684\u201390.","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"5604_CR9","doi-asserted-by":"crossref","unstructured":"Kase AM, George DJ, Ramalingam S. Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030665"},{"issue":"2","key":"5604_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine. 2007;356(2):115\u201324.","journal-title":"The New England journal of medicine"},{"issue":"5","key":"5604_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/annonc\/mdp466","volume":"21","author":"R Thiam","year":"2010","unstructured":"Thiam R, Fournier LS, Trinquart L, Medioni J, Chatellier G, Balvay D, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Annals of oncology: official journal of the European Society for Medical Oncology. 2010;21(5):936\u201341.","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"13","key":"5604_CR12","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25(13):1753\u20139.","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"5","key":"5604_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/sj.bjc.6605567","volume":"102","author":"AA van der Veldt","year":"2010","unstructured":"van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010;102(5):803\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"5604_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/cbt.9.1.10340","volume":"9","author":"PD Nathan","year":"2010","unstructured":"Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther. 2010;9(1):15\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"5604_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1148\/radiol.14132702","volume":"273","author":"Y Thian","year":"2014","unstructured":"Thian Y, Gutzeit A, Koh DM, Fisher R, Lote H, Larkin J, et al. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib. Radiology. 2014;273(2):452\u201361.","journal-title":"Radiology"},{"issue":"1","key":"5604_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2214\/AJR.09.2941","volume":"194","author":"AD Smith","year":"2010","unstructured":"Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194(1):157\u201365.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"5604_CR17","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2214\/AJR.09.3456","volume":"194","author":"AD Smith","year":"2010","unstructured":"Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194(6):1470\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"5604_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1148\/radiol.2016160143","volume":"281","author":"AD Smith","year":"2016","unstructured":"Smith AD, Zhang X, Bryan J, Souza F, Roda M, Sirous R, et al. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy. Radiology. 2016;281(2):484\u201398.","journal-title":"Radiology"},{"issue":"2","key":"5604_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1148\/radiol.10091362","volume":"256","author":"LS Fournier","year":"2010","unstructured":"Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology. 2010;256(2):511\u20138.","journal-title":"Radiology"},{"issue":"17","key":"5604_CR20","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-08-0417","volume":"14","author":"C de Bazelaire","year":"2008","unstructured":"de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787\/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(17):5548\u201354.","journal-title":"Clin Cancer Res"},{"key":"5604_CR21","doi-asserted-by":"crossref","unstructured":"Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD, et al. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines. 2023;11(4).","DOI":"10.3390\/biomedicines11041071"},{"issue":"19","key":"5604_CR22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015;373(19):1803\u201313.","journal-title":"The New England journal of medicine"},{"key":"5604_CR23","doi-asserted-by":"publisher","first-page":"982983","DOI":"10.3389\/fonc.2022.982983","volume":"12","author":"AM Berz","year":"2022","unstructured":"Berz AM, Dromain C, Vietti-Violi N, Boughdad S, Duran R. Tumor response assessment on imaging following immunotherapy. Front Oncol. 2022;12:982983.","journal-title":"Front Oncol"},{"issue":"3","key":"5604_CR24","doi-asserted-by":"publisher","first-page":"e143-e52","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 2017;18(3):e143-e52.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"5604_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","volume":"9","author":"L Goldfarb","year":"2019","unstructured":"Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9(1):8.","journal-title":"EJNMMI Res"},{"key":"5604_CR26","doi-asserted-by":"crossref","unstructured":"Zheng J, Zhou X, Fu Y, Chen Q. Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1\/PD-L1 Antibody and the Mechanisms of Its Occurrence. Cancers (Basel). 2023;15(4).","DOI":"10.3390\/cancers15041314"},{"issue":"1","key":"5604_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","volume":"297","author":"HJ Park","year":"2020","unstructured":"Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, et al. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology. 2020;297(1):87\u201396.","journal-title":"Radiology"},{"issue":"2","key":"5604_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2019-0636","volume":"25","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2020;25(2):94\u20138.","journal-title":"Oncologist"},{"issue":"3","key":"5604_CR29","doi-asserted-by":"publisher","first-page":"e6970","DOI":"10.1002\/cam4.6970","volume":"13","author":"MJ Kim","year":"2024","unstructured":"Kim MJ, Hong SPD, Park Y, Chae YK. Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta-analysis. Cancer Med. 2024;13(3):e6970.","journal-title":"Cancer Med"},{"key":"5604_CR30","first-page":"102824","volume":"56","author":"A Feinaj","year":"2024","unstructured":"Feinaj A, Fox E, Sinibaldi V, Kleinberg L, Ged Y. Abscopal effect following checkpoint inhibitor therapy and localized radiotherapy for metastatic clear cell renal cell carcinoma: A case report. Urol Case Rep. 2024;56:102824.","journal-title":"Urol Case Rep"},{"key":"5604_CR31","doi-asserted-by":"crossref","unstructured":"Laurent PA, Shi L, Bouarroudj L, Benzazon N, Gerb\u00e9 De Thor\u00e9 M, Liu W, et al. Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect. J Immunother Cancer. 2025;13(6).","DOI":"10.1136\/jitc-2025-011487"},{"key":"5604_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fphar.2019.00511","volume":"10","author":"M Trommer","year":"2019","unstructured":"Trommer M, Yeo SY, Persigehl T, Bunck A, Gr\u00fcll H, Schlaak M, et al. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front Pharmacol. 2019;10:511.","journal-title":"Front Pharmacol"},{"issue":"12","key":"5604_CR33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019;380(12):1116\u201327.","journal-title":"The New England journal of medicine"},{"issue":"12","key":"5604_CR34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019;380(12):1103\u201315.","journal-title":"The New England journal of medicine"},{"issue":"23","key":"5604_CR35","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5604_CR36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clgc.2023.03.003","volume":"21","author":"L Haaker","year":"2023","unstructured":"Haaker L, Baldewijns M, De Wever L, Albersen M, Debruyne PR, Wynendaele W, et al. Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. Clin Genitourin Cancer. 2023;21(4):442\u201351.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"5604_CR37","first-page":"632","volume":"23","author":"N Schmidt","year":"2013","unstructured":"Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. European radiology. 2013;23(3):632\u20139.","journal-title":"European radiology"},{"key":"5604_CR38","doi-asserted-by":"publisher","first-page":"110802","DOI":"10.1016\/j.radonc.2025.110802","volume":"206","author":"L Cai","year":"2025","unstructured":"Cai L, Chen K, Pan Q, Zhang X, Liu R, Liu Y, et al. Response evaluation and tumor shrinkage pattern post-SBRT for renal cell carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2025;206:110802.","journal-title":"Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology"},{"issue":"3","key":"5604_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2214\/AJR.20.22837","volume":"215","author":"R Thomas","year":"2020","unstructured":"Thomas R, Howard SA, Laferriere SL, Braschi-Amirfarzan M. A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapy-Related Toxicity: A Primer for the Radiologist. AJR Am J Roentgenol. 2020;215(3):770\u201380.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"5604_CR40","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1148\/rg.2017160162","volume":"37","author":"ST Chang","year":"2017","unstructured":"Chang ST, Menias CO, Lubner MG, Mellnick VM, Hara AK, Desser TS. Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. Radiographics. 2017;37(5):1461\u201382.","journal-title":"Radiographics"},{"key":"5604_CR41","doi-asserted-by":"crossref","unstructured":"Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. European journal of cancer (Oxford, England: 1990). 2012;48(10):1519-24.","DOI":"10.1016\/j.ejca.2012.03.012"},{"issue":"4","key":"5604_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, et al. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases. 2019;7(4):405\u201318.","journal-title":"World J Clin Cases"},{"issue":"12","key":"5604_CR43","doi-asserted-by":"publisher","first-page":"8868","DOI":"10.1007\/s00330-021-07925-7","volume":"31","author":"N Pisuchpen","year":"2021","unstructured":"Pisuchpen N, Durbin SM, Mooradian MJ, Fintelmann FJ, Reynolds KL, Dougan M, et al. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. European radiology. 2021;31(12):8868\u201378.","journal-title":"European radiology"},{"issue":"5","key":"5604_CR44","doi-asserted-by":"publisher","first-page":"W468-74","DOI":"10.2214\/AJR.12.9751","volume":"200","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468-74.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"5604_CR45","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1148\/rg.220108","volume":"42","author":"GS Shroff","year":"2022","unstructured":"Shroff GS, Strange CD, Ahuja J, Altan M, Sheshadri A, Unlu E, et al. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer. Radiographics. 2022;42(7):1956\u201374.","journal-title":"Radiographics"},{"issue":"6","key":"5604_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","volume":"82","author":"M Ali","year":"2022","unstructured":"Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, et al. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Eur Urol. 2022;82(6):613\u201322.","journal-title":"Eur Urol"},{"issue":"1","key":"5604_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.euf.2022.08.016","volume":"9","author":"J Le Guevelou","year":"2023","unstructured":"Le Guevelou J, Sargos P, Siva S, Ploussard G, Ost P, Gillessen S, et al. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. Eur Urol Focus. 2023;9(1):114\u201324.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"5604_CR48","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","volume":"2","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515\u201323.","journal-title":"Eur Urol Oncol"},{"key":"5604_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13014-015-0528-z","volume":"10","author":"B Altoos","year":"2015","unstructured":"Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, et al. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015;10:218.","journal-title":"Radiat Oncol"},{"issue":"6","key":"5604_CR50","doi-asserted-by":"publisher","first-page":"e589-e96","DOI":"10.1016\/j.prro.2015.05.004","volume":"5","author":"A Amini","year":"2015","unstructured":"Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol. 2015;5(6):e589-e96.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"5604_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/1754-9485.13847","volume":"69","author":"A Lasocki","year":"2025","unstructured":"Lasocki A, Sia J, Stuckey SL. Differentiation Between Radiation Necrosis and True Tumour Progression After Radiotherapy to Intracranial Metastases. J Med Imaging Radiat Oncol. 2025;69(3):414\u201324.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"3","key":"5604_CR52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","volume":"12","author":"HY Wang","year":"2012","unstructured":"Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma. Cancer Imaging. 2012;12(3):464\u201374.","journal-title":"Cancer Imaging"},{"issue":"7","key":"5604_CR53","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1007\/s11604-025-01761-1","volume":"43","author":"K Hirota","year":"2025","unstructured":"Hirota K, Ueno Y, Nogami M, Hyodo T, Tsuboyama T, Sofue K, et al. Role of (18)F-FDG-PET in renal tumors: insights from WHO 2022 classification. Jpn J Radiol. 2025;43(7):1078\u201389.","journal-title":"Jpn J Radiol"},{"issue":"9","key":"5604_CR54","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00432-002-0370-1","volume":"128","author":"HC Wu","year":"2002","unstructured":"Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol. 2002;128(9):503\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"5604_CR55","first-page":"137","volume":"24","author":"L Vercellino","year":"2009","unstructured":"Vercellino L, Bousquet G, Baillet G, Barr\u00e9 E, Mathieu O, Just PA, et al. 18F-FDG PET\/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24(1):137\u201344.","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"5604_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.clon.2010.11.006","volume":"23","author":"ME Revheim","year":"2011","unstructured":"Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Foss\u00e5 SD, Lilleby W. Combined positron emission tomography\/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2011;23(5):339\u201343.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"18","key":"5604_CR57","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-10-3309","volume":"17","author":"I Kayani","year":"2011","unstructured":"Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET\/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011;17(18):6021\u20138.","journal-title":"Clin Cancer Res"},{"key":"5604_CR58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fonc.2016.00201","volume":"6","author":"Y Liu","year":"2016","unstructured":"Liu Y. The Place of FDG PET\/CT in Renal Cell Carcinoma: Value and Limitations. Front Oncol. 2016;6:201.","journal-title":"Front Oncol"},{"issue":"3","key":"5604_CR59","doi-asserted-by":"publisher","first-page":"e438658","DOI":"10.1200\/EDBK_438658","volume":"44","author":"M Ali","year":"2024","unstructured":"Ali M, Eid M, Saliby RM, Choi S, McKay RR, Siva S, et al. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. Am Soc Clin Oncol Educ Book. 2024;44(3):e438658.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"5604_CR60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ucl.2020.04.005","volume":"47","author":"SVL Vig","year":"2020","unstructured":"Vig SVL, Zan E, Kang SK. Imaging for Metastatic Renal Cell Carcinoma. Urol Clin North Am. 2020;47(3):281\u201391.","journal-title":"Urol Clin North Am"},{"issue":"9","key":"5604_CR61","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00256-024-04723-2","volume":"53","author":"FE Lecouvet","year":"2024","unstructured":"Lecouvet FE, Chabot C, Taihi L, Kirchgesner T, Triqueneaux P, Malghem J. Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it. Skeletal Radiol. 2024;53(9):1815\u201331.","journal-title":"Skeletal Radiol"},{"issue":"1","key":"5604_CR62","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s00330-022-09007-8","volume":"33","author":"O Chiabai","year":"2023","unstructured":"Chiabai O, Van Nieuwenhove S, Vekemans MC, Tombal B, Peeters F, Wuts J, et al. Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma? European radiology. 2023;33(1):244\u201357.","journal-title":"European radiology"},{"issue":"7","key":"5604_CR63","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/0284186X.2020.1750696","volume":"59","author":"B Beuselinck","year":"2020","unstructured":"Beuselinck B, Pans S, Bielen J, De Wever L, Noppe N, Vanderschueren G, et al. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors. Acta Oncol. 2020;59(7):818\u201324.","journal-title":"Acta Oncol"},{"issue":"5","key":"5604_CR64","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3109\/02841851003724846","volume":"51","author":"I Platzek","year":"2010","unstructured":"Platzek I, Zastrow S, Deppe PE, Grimm MO, Wirth M, Laniado M, et al. Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiol. 2010;51(5):581\u20139.","journal-title":"Acta Radiol"},{"issue":"3","key":"5604_CR65","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/bjc.2013.790","volume":"110","author":"N Bharwani","year":"2014","unstructured":"Bharwani N, Miquel ME, Powles T, Dilks P, Shawyer A, Sahdev A, et al. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. Br J Cancer. 2014;110(3):616\u201324.","journal-title":"Br J Cancer"},{"key":"5604_CR66","doi-asserted-by":"publisher","first-page":"111840","DOI":"10.1016\/j.ejrad.2024.111840","volume":"182","author":"R Garc\u00eda-Figueiras","year":"2025","unstructured":"Garc\u00eda-Figueiras R, Baleato-Gonz\u00e1lez S. Quantitative multi-energy CT in oncology: State of the art and future directions. Eur J Radiol. 2025;182:111840.","journal-title":"Eur J Radiol"},{"key":"5604_CR67","doi-asserted-by":"crossref","unstructured":"Tortora M, Gemini L, D\u2019Iglio I, Ugga L, Spadarella G, Cuocolo R. Spectral Photon-Counting Computed Tomography: A Review on Technical Principles and Clinical Applications. J Imaging. 2022;8(4).","DOI":"10.3390\/jimaging8040112"},{"issue":"8","key":"5604_CR68","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1007\/s00330-025-11351-4","volume":"35","author":"N Wiley","year":"2025","unstructured":"Wiley N, Zecevic M, Ho V, Stolzberg MJ, Cox D, Soloff EV, et al. Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients. European radiology. 2025;35(8):4417\u201328.","journal-title":"European radiology"},{"issue":"5","key":"5604_CR69","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2214\/AJR.21.26911","volume":"218","author":"A Drljevic-Nielsen","year":"2022","unstructured":"Drljevic-Nielsen A, Donskov F, Mains JR, Andersen MB, Thorup K, Thygesen J, et al. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma. AJR Am J Roentgenol. 2022;218(5):867\u201376.","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 1","key":"5604_CR70","doi-asserted-by":"publisher","first-page":"122s-50s","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122s-50s.","journal-title":"J Nucl Med"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05604-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:03:16Z","timestamp":1782712996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05604-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":70,"alternative-id":["5604"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05604-z","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}